1SXP SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About SCHOTT Pharma (ETR: 1SXP)
›
SCHOTT Pharma (ETR: 1SXP) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 5,002 employees.
The shares were at 22.60 EUR on 19 November 2026, up 24.8% over 52 weeks. Its 52-week range is 12.62 EUR to 26.20 EUR: the price is 13.7% below the high and 79.1% above the low.
At a market capitalisation of 3.40B EUR, it trades at 25.1 times trailing earnings and 20.6 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 49.2, a discount of 49% for 1SXP. It pays a dividend yielding 0.80% (it pays out 20% of its earnings), against a median of 0.93% among the dividend payers in that peer group.
SCHOTT Pharma reports return on equity of 16.4%, an operating margin of 16.4% and revenue up 10.0% year over year.
Its debt exceeds its cash by 283.38M EUR, a debt-to-equity ratio of 0.09. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 13 analysts cover the stock, with an average rating of Buy; their mean price target of 25.03 EUR is 10.8% above the current price. The next earnings report is expected on 10 December 2026.